Zelira Therapeutics
  • HOME
  • ABOUT
    • OUR COMPANY
    • BOARD
    • ADVISORY BOARD
    • LOCATIONS
    • MEDICAL CANNABIS
      • SCIENCE
      • LEGALISED MARKETS
  • RESEARCH
    • PRODUCT PIPELINE
    • PRECLINICAL
      • PANCREATIC CANCER
      • BREAST CANCER
      • BRAIN CANCER
      • DIABETES RELATED COGNITIVE DECLINE
    • CLINICAL
      • CHRONIC PAIN
      • INSOMNIA
      • AUTISM
  • PRODUCTS
    • Doctors
    • Pharmacists
    • Patients
  • INVESTORS
    • ASX ANNOUNCEMENTS
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
    • PRESENTATIONS & VIDEOS
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • REPORTS
    • STOCK INFORMATION
    • CORPORATE GOVERNANCE
  • MEDIA
    • VIDEOS & AUDIOS
    • ARTICLES
    • Autism Symposium
  • CONTACT
  • HOME
  • ABOUT
    •         - OUR COMPANY
    •         - BOARD
    •         - ADVISORY BOARD
    •         - LOCATIONS
    •         - MEDICAL CANNABIS
      •                 - SCIENCE
      •                 - LEGALISED MARKETS
  • RESEARCH
    •         - PRODUCT PIPELINE
    •         - PRECLINICAL
      •                 - PANCREATIC CANCER
      •                 - BREAST CANCER
      •                 - BRAIN CANCER
      •                 - DIABETES RELATED COGNITIVE DECLINE
    •         - CLINICAL
      •                 - CHRONIC PAIN
      •                 - INSOMNIA
      •                 - AUTISM
  • PRODUCTS
    •         - Doctors
    •         - Pharmacists
    •         - Patients
  • INVESTORS
    •         - ASX ANNOUNCEMENTS
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
    •         - PRESENTATIONS & VIDEOS
      •                 - 2020
      •                 - 2019
      •                 - 2018
      •                 - 2017
      •                 - 2016
      •                 - 2015
    •         - REPORTS
    •         - STOCK INFORMATION
    •         - CORPORATE GOVERNANCE
  • MEDIA
    •         - VIDEOS & AUDIOS
    •         - ARTICLES
    •         - Autism Symposium
  • CONTACT

Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme

By Zelira TherapeuticsSeptember 16, 2020articles-2020

Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme

Medicinal cannabis trial could help retired AFL players manage chronic pain
Zelira Therapeutics’ insomnia treatment gets TGA tick

SUBSCRIBE

Zelira TherapeuticsFollow

Zelira Therapeutics
5h

Cannabis LAB - Elevate Your Grind interview with
Dr. Oludare Odumosu, CEO USA at Zelira Therapeutics on 20 October.
https://t.co/aSuYVxzRJR

Twitter
Load More...

CONTACT US






Copyright © Zelira Therapeutics. All rights reserved. | Disclaimer.